Drug Profile
Research programme: botulism vaccines - DynPort Vaccine Company
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
- Developer Cambridge Biostability; DynPort Vaccine Company
- Class
- Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Botulism
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Botulism in USA (Parenteral, Injection)
- 03 Apr 2008 Preclinical development of a vaccine against seven botulinum neurotoxins is ongoing